Cross-Linked Conjugated Polymer Nanoparticles for High Purity

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Current photoluminescent conjugated polymer nanoparticles (CPNs) face limitations in widespread adoption due to challenges in production processes, manufacturing control, and purity, especially for biological applications.

Innovation Solution

A nanoparticle composition comprising π-conjugated cross-linked polymers, formed through emulsion, miniemulsion, or dispersion polymerization techniques, offering improved manufacturing simplicity, tunability, and high purity.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Manufacturing precision

If conventional CPN synthesis methods are used, then photoluminescent properties are achieved, but manufacturing control and purity are insufficient

Engineering Contradiction:
Improvemanufacturing controlVSAvoidproduction process complexity
Core Design Contradiction:
Manufacturing precisionVSEase of manufacture

Solution Approach 1:

The patent applies parameter changes by systematically varying reaction conditions including monomer to crosslinker ratios (0.1-20 mol%), solvent types, temperature ranges, and reaction times to optimize nanoparticle formation. This enables precise control over particle size (10-200 nm), polydispersity index, and photoluminescent properties while maintaining manufacturing simplicity through conventional polymerization techniques

Inventive Principle:
Principle #35Parameter changes

Solution Approach 2:

The patent employs composite materials by incorporating crosslinkers into the polymerization reaction to create crosslinked polymer networks within nanoparticles. This composite structure comprising conjugated polymer chains and crosslinking agents provides enhanced manufacturing control and purity while preserving the desired photoluminescent characteristics

Inventive Principle:
Principle #40Composite materials

2Object-affected harmful factors

If CPNs are used as QD alternatives, then toxicity is reduced, but purity for biological applications remains insufficient

Engineering Contradiction:
ImprovetoxicityVSAvoidpurity
Core Design Contradiction:
Object-affected harmful factorsVSManufacturing precision

Solution Approach 1:

The patent applies the extraction principle by removing impurities and unwanted byproducts through optimized purification protocols including filtration, centrifugation, and solvent washing steps. This extraction process achieves high purity nanoparticles suitable for biological applications while maintaining the intrinsic low toxicity of conjugated polymer materials compared to quantum dots

Inventive Principle:
Principle #2Taking out (Extraction)

Solution Approach 2:

The patent uses parameter changes by adjusting reaction conditions such as monomer purity, solvent selection, and reaction temperature to minimize impurity formation during synthesis. This proactive approach to purity control through parameter optimization ensures high-quality nanoparticles for biological use while preserving the toxicity advantages of CPNs

Inventive Principle:
Principle #35Parameter changes

3Length of moving object

If particle size is reduced to 10-200 nm, then cellular internalization is enabled, but manufacturing control becomes more difficult

Engineering Contradiction:
Improveparticle sizeVSAvoidsize control
Core Design Contradiction:
Length of moving objectVSManufacturing precision

Solution Approach 1:

The patent applies parameter changes by systematically varying reaction conditions including monomer concentration, crosslinker amount, solvent type, temperature, and reaction time to precisely control nanoparticle size within the 10-200 nm range. These parameter adjustments enable cellular internalization while maintaining narrow size distributions through optimized polymerization kinetics

Inventive Principle:
Principle #35Parameter changes

Solution Approach 2:

The patent employs dynamics by utilizing the time-dependent nature of polymerization reactions to control particle growth. By adjusting reaction duration, temperature profiles, and addition rates of monomers and crosslinkers, the patent dynamically controls nanoparticle formation and size distribution, achieving precise size control for cellular uptake applications

Inventive Principle:
Principle #15Dynamics

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The nanoparticle composition achieves enhanced purity and stability, making it suitable for biological applications and overcoming the toxicity and control issues associated with existing CPNs.

Implementation Method 1

comprising a plurality of nanoparticles formed from π-conjugated cross-linked polymers

Methodology Applied
Scientific EffectPolymerization: Photopolymerisation

Implementation Method 2

Photoluminescent conjugated polymer nanoparticles (CPNs)

Methodology Applied
Scientific EffectPhotoluminescence: Photoluminescence

Data Source

PatentEP3169722B9nanoparticles
Publication Date: 2025.06.18 CHROMITION
  • EP3169722B9 patent drawingFigure 1
  • EP3169722B9 patent drawingFigure 2
  • EP3169722B9 patent drawingFigure 3

AI summary

Nanoparticle compositions comprising nanoparticles formed from π-conjugated cross- linked polymers are disclosed, together with their methods of manufacture and their applications. Owing to the nature of the cross-links formed therein, the nanoparticle compositions afford a high degree of manufacturing flexibility and control, as well as being amenable to facile purification for the purpose of imaging and electronics applications.